Blastic Mantle Cell Lymphoma Developing Concurrently in a Patient with Chronic Myelogenous Leukemia and a Review of the Literature

Eve Rodler, Jeanna L Welborn, Sandra Hatcher, Katherine Unger, Edward Larkin, Paul H. Gumerlock, Theodore Wun, Carol M Richman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Non-Hodgkin's lymphoma (NHL) occurring as a synchronous malignancy with chronic myelogenous leukemia (CML) is rare. To our knowledge, this is the first case reported of a patient who developed mantle cell lymphoma (MCL) after therapy with imatinib mesylate for CML. After a 3-year history of CML, the patient developed a lymphocytosis associated with diarrhea, anorexia, and weight loss. Imaging studies revealed abdominal adenopathy and extensive lymphomatous infiltration of the liver, stomach, pancreas, and kidneys. Flow cytometric and cytogenetic studies were consistent with MCL. Fluorescence in situ hybridization (FISH) of the bone marrow revealed a genetically distinct lymphoid neoplasm rather than an extramedullary blast crisis of CML. The development of lung cancer, prostate cancer, CML and MCL in this patient suggests a genetic predisposition, although other factors, including environmental exposures and therapy with imatinib mesylate could have had a contributory or synergistic role in the development of MCL.

Original languageEnglish (US)
Pages (from-to)231-238
Number of pages8
JournalAmerican Journal of Hematology
Volume75
Issue number4
DOIs
StatePublished - Apr 2004

Fingerprint

Mantle-Cell Lymphoma
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Prostatic Neoplasms
Implosive Therapy
Blast Crisis
Lymphocytosis
Environmental Exposure
Anorexia
Genetic Predisposition to Disease
Fluorescence In Situ Hybridization
Cytogenetics
Non-Hodgkin's Lymphoma
Weight Loss
Pancreas
Diarrhea
Lung Neoplasms
Neoplasms
Stomach
Bone Marrow
Kidney

Keywords

  • B-cell lymphoma
  • Blastic variant
  • Chronic myelogenous leukemia
  • Imatinib mesylate
  • Mantle cell lymphoma
  • STI571

ASJC Scopus subject areas

  • Hematology

Cite this

Blastic Mantle Cell Lymphoma Developing Concurrently in a Patient with Chronic Myelogenous Leukemia and a Review of the Literature. / Rodler, Eve; Welborn, Jeanna L; Hatcher, Sandra; Unger, Katherine; Larkin, Edward; Gumerlock, Paul H.; Wun, Theodore; Richman, Carol M.

In: American Journal of Hematology, Vol. 75, No. 4, 04.2004, p. 231-238.

Research output: Contribution to journalArticle

@article{1a167cfd4fe0482aa13c83c77a5c37a0,
title = "Blastic Mantle Cell Lymphoma Developing Concurrently in a Patient with Chronic Myelogenous Leukemia and a Review of the Literature",
abstract = "Non-Hodgkin's lymphoma (NHL) occurring as a synchronous malignancy with chronic myelogenous leukemia (CML) is rare. To our knowledge, this is the first case reported of a patient who developed mantle cell lymphoma (MCL) after therapy with imatinib mesylate for CML. After a 3-year history of CML, the patient developed a lymphocytosis associated with diarrhea, anorexia, and weight loss. Imaging studies revealed abdominal adenopathy and extensive lymphomatous infiltration of the liver, stomach, pancreas, and kidneys. Flow cytometric and cytogenetic studies were consistent with MCL. Fluorescence in situ hybridization (FISH) of the bone marrow revealed a genetically distinct lymphoid neoplasm rather than an extramedullary blast crisis of CML. The development of lung cancer, prostate cancer, CML and MCL in this patient suggests a genetic predisposition, although other factors, including environmental exposures and therapy with imatinib mesylate could have had a contributory or synergistic role in the development of MCL.",
keywords = "B-cell lymphoma, Blastic variant, Chronic myelogenous leukemia, Imatinib mesylate, Mantle cell lymphoma, STI571",
author = "Eve Rodler and Welborn, {Jeanna L} and Sandra Hatcher and Katherine Unger and Edward Larkin and Gumerlock, {Paul H.} and Theodore Wun and Richman, {Carol M}",
year = "2004",
month = "4",
doi = "10.1002/ajh.20025",
language = "English (US)",
volume = "75",
pages = "231--238",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Blastic Mantle Cell Lymphoma Developing Concurrently in a Patient with Chronic Myelogenous Leukemia and a Review of the Literature

AU - Rodler, Eve

AU - Welborn, Jeanna L

AU - Hatcher, Sandra

AU - Unger, Katherine

AU - Larkin, Edward

AU - Gumerlock, Paul H.

AU - Wun, Theodore

AU - Richman, Carol M

PY - 2004/4

Y1 - 2004/4

N2 - Non-Hodgkin's lymphoma (NHL) occurring as a synchronous malignancy with chronic myelogenous leukemia (CML) is rare. To our knowledge, this is the first case reported of a patient who developed mantle cell lymphoma (MCL) after therapy with imatinib mesylate for CML. After a 3-year history of CML, the patient developed a lymphocytosis associated with diarrhea, anorexia, and weight loss. Imaging studies revealed abdominal adenopathy and extensive lymphomatous infiltration of the liver, stomach, pancreas, and kidneys. Flow cytometric and cytogenetic studies were consistent with MCL. Fluorescence in situ hybridization (FISH) of the bone marrow revealed a genetically distinct lymphoid neoplasm rather than an extramedullary blast crisis of CML. The development of lung cancer, prostate cancer, CML and MCL in this patient suggests a genetic predisposition, although other factors, including environmental exposures and therapy with imatinib mesylate could have had a contributory or synergistic role in the development of MCL.

AB - Non-Hodgkin's lymphoma (NHL) occurring as a synchronous malignancy with chronic myelogenous leukemia (CML) is rare. To our knowledge, this is the first case reported of a patient who developed mantle cell lymphoma (MCL) after therapy with imatinib mesylate for CML. After a 3-year history of CML, the patient developed a lymphocytosis associated with diarrhea, anorexia, and weight loss. Imaging studies revealed abdominal adenopathy and extensive lymphomatous infiltration of the liver, stomach, pancreas, and kidneys. Flow cytometric and cytogenetic studies were consistent with MCL. Fluorescence in situ hybridization (FISH) of the bone marrow revealed a genetically distinct lymphoid neoplasm rather than an extramedullary blast crisis of CML. The development of lung cancer, prostate cancer, CML and MCL in this patient suggests a genetic predisposition, although other factors, including environmental exposures and therapy with imatinib mesylate could have had a contributory or synergistic role in the development of MCL.

KW - B-cell lymphoma

KW - Blastic variant

KW - Chronic myelogenous leukemia

KW - Imatinib mesylate

KW - Mantle cell lymphoma

KW - STI571

UR - http://www.scopus.com/inward/record.url?scp=1842583992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842583992&partnerID=8YFLogxK

U2 - 10.1002/ajh.20025

DO - 10.1002/ajh.20025

M3 - Article

C2 - 15054816

AN - SCOPUS:1842583992

VL - 75

SP - 231

EP - 238

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -